These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32653374)

  • 1. Kinetic and thermodynamic insights into interaction of erlotinib with epidermal growth factor receptor: Surface plasmon resonance and molecular docking approaches.
    Mohammadzadeh-Asl S; Aghanejad A; Yekta R; de la Guardia M; Ezzati Nazhad Dolatabadi J; Keshtkar A
    Int J Biol Macromol; 2020 Nov; 163():954-958. PubMed ID: 32653374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies.
    Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K
    Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bovine serum albumin binding study to erlotinib using surface plasmon resonance and molecular docking methods.
    Taghipour P; Zakariazadeh M; Sharifi M; Ezzati Nazhad Dolatabadi J; Barzegar A
    J Photochem Photobiol B; 2018 Jun; 183():11-15. PubMed ID: 29679689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
    Yang X; Hou Z; Wang D; Mou Y; Guo C
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational identification of new TKI as potential noncovalent reversible EGFR
    Abdelmalek D; Smaoui F; Frikha F; Ben Marzoug R; Msalbi D; Souissi A; Aifa MS
    J Biomol Struct Dyn; 2024 Jun; 42(9):4870-4887. PubMed ID: 37349947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
    Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
    Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imidazole[1,5-a]pyridine derivatives as EGFR tyrosine kinase inhibitors unraveled by umbrella sampling and steered molecular dynamics simulations.
    Truong DT; Ho K; Nhi HTY; Nguyen VH; Dang TT; Nguyen MT
    Sci Rep; 2024 May; 14(1):12218. PubMed ID: 38806555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography.
    Yang L; Zhu M; Kang Y; Yang T; Ma W
    J Mol Recognit; 2018 Jun; 31(6):e2701. PubMed ID: 29363191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
    Minnelli C; Laudadio E; Mobbili G; Galeazzi R
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 1,3,4-oxadiazole derivatives of naproxen targeting EGFR: Synthesis, molecular docking studies, and cytotoxic evaluation.
    Alsaad HN; Al-Jasani BM; Mahmood AAR; Tahtamouni LH; Saleh KM; AlSakhen MF; Kanaan SI; Yasin SR
    Drug Dev Res; 2024 Aug; 85(5):e22231. PubMed ID: 38956926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
    Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH
    Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies.
    Aiebchun T; Mahalapbutr P; Auepattanapong A; Khaikate O; Seetaha S; Tabtimmai L; Kuhakarn C; Choowongkomon K; Rungrotmongkol T
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33921332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines.
    Reiersølmoen AC; Aarhus TI; Eckelt S; Nørsett KG; Sundby E; Hoff BH
    Bioorg Chem; 2019 Jul; 88():102918. PubMed ID: 30999245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
    Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
    Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
    Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
    Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Silico Identification of Novel Erlotinib Analogues Against Epidermal Growth Factor Receptor.
    Sheikh IA; Hassan HM
    Anticancer Res; 2016 Nov; 36(11):6125-6132. PubMed ID: 27793941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
    Li YL; Hu X; Li QY; Wang F; Zhang B; Ding K; Tan BQ; Lin NM; Zhang C
    Mol Med Rep; 2018 Oct; 18(4):3882-3890. PubMed ID: 30106133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, Molecular Docking, and Biological Evaluation of Isatin-Based Fused Heterocycles As Epidermal Growth Factor Receptor Inhibitors.
    Kumar A; Kumar B; Bhatia R
    Assay Drug Dev Technol; 2023 Jul; 21(5):222-233. PubMed ID: 37439798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.